CJC-1295 (no DAC) + Ipamorelin - 10 mg

This research blend combines two growth hormone–axis peptides in a single lyophilized vial: CJC-1295 without DAC (Mod GRF 1-29) and ipamorelin. The formulation pairs a modified GHRH(1-29) analog with a selective growth hormone secretagogue receptor (GHS-R) agonist, allowing concurrent investigation of GHRH and ghrelin / GHS pathway activation. CJC-1295 No DAC is a 29-amino-acid modified GRF(1-29) sequence with D-Ala², Gln⁸, Ala¹⁵, and Leu²⁷ substitutions designed to resist DPP-IV cleavage, offering a shorter pulsatile pharmacokinetic profile compared to the DAC-linked variant. Ipamorelin is a selective pentapeptide GHS-R1a agonist studied for its specificity over cortisol, prolactin, ACTH, and aldosterone pathways. The 10 mg blend (5 mg + 5 mg) is one of the most widely cited GH-axis research stack combinations in the peptide research literature, paired as a tool for studying GHRH + GHS-R receptor synergy in pituitary GH release research.

Benefits (Research Focus)

• Combined GHRH + GHS-R activation — studied for paired pathway stimulation of the somatotropic axis

• Pulsatile GH release — investigated for physiologic-pattern growth hormone release in research models

• IGF-1 axis signaling — explored for downstream hepatic IGF-1 production and somatotropic endpoints

• Receptor-pathway differentiation — examined for paired GHRH receptor and GHS-R1a receptor pharmacology

• Hormone selectivity — researched for ipamorelin's reported minimal off-target effects on cortisol, prolactin, and ACTH

What Researchers Look At

• Plasma GH and IGF-1 dynamics following paired peptide administration

• Pulsatile vs sustained GH release across paired GHRH and GHS-R stimulation

• Cortisol, prolactin, and ACTH response panels (selectivity markers)

• DPP-IV resistance and peptide pharmacokinetic profiles across components

• Comparative pharmacology versus tesamorelin-based blends and single-component administration

Quick Specs

• Form: Lyophilized white powder

• CJC-1295 (no DAC): 5 mg per vial

• Ipamorelin: 5 mg per vial

• Total Peptide Content: 10 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC (per component)

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound 1: CJC-1295 without DAC (Mod GRF 1-29)

• Synonyms: Mod GRF 1-29; Modified GRF(1-29); CJC-1295 No DAC; tetrasubstituted GRF(1-29)

• Class: Modified GHRH(1-29) analog; 29 amino acids

• Modification: D-Ala², Gln⁸, Ala¹⁵, Leu²⁷ substitutions for DPP-IV resistance and stability

• Formula / M.W.: C₁₅₂H₂₅₂N₄₄O₄₂, ~3367.95 g/mol

• CAS: 863288-34-0

• Compound 2: Ipamorelin

• Synonyms: NNC 26-0161

• Class: Selective ghrelin / GHS-R1a agonist; pentapeptide

• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

• Formula / M.W.: C₃₈H₄₉N₉O₅, ~711.85 g/mol

• CAS: 170851-70-4

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• CJC-1295 / Ipamorelin Blend VPeptide Canada — December 11, 2025

• CJC / Ipa Blend VPeptide Canada — March 16, 2026

• CJC / Ipa Blend VPeptide Canada — June 5, 2026